Baby Boy with SMA Reaches Motor Milestones with Early Evrysdi Use

A baby boy diagnosed with Spinal Muscular Atrophy (SMA) has achieved significant motor milestones thanks to early treatment with Evrysdi, a revolutionary medication approved by the FDA in 2020. SMA is a genetic disorder that affects the nerve cells responsible for controlling voluntary muscle movement, with approximately 1 in 11,000 babies born with the condition. The baby's progress is a testament to the effectiveness of Evrysdi, which has been shown to improve motor function and survival in SMA patients. With over 2,500 patients treated worldwide, Evrysdi has become a beacon of hope for families affected by SMA. As of 2022, the medication has been approved in over 40 countries, including the United States, Canada, and the European Union. The baby boy's remarkable story highlights the importance of early diagnosis and treatment, with 80% of SMA patients experiencing significant improvements in motor function when treated with Evrysdi before the age of 2.